MagForce : to participate at SNO 2017 Annual Meeting from November 16-19 in San Francisco, USA

MagForce AG to participate at SNO 2017 Annual Meeting from November 16-19 in San Francisco, USA

Berlin, Germany, and Nevada, USA, November 14, 2017 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, SNO 2017, held from November 16-19, 2017, in San Francisco, California, USA.

Reporting on their experiences with NanoTherm^(R) therapy, PD Dr Dr Oliver Grauer, Head of Neuro-Oncology at the Department of Neurology (Director: Prof. Dr. Heinz Wiendl) and part of the team of Prof Dr Walter Stummer, Director of the Department of Neurosurgery at the University Hospital Münster, Germany, that are treating patients with NanoTherm^(R) therapy, will give an oral presentation on the Münster Team's experience with intracavitary thermotherapy with iron-oxide nanoparticles in combination with radiotherapy as a promising treatment modality in recurrent glioblastoma. The oral presentation will be held on Friday, November 17, 2017, 13:45 PDT as part of the session on 'Experimental Therapeutics and Tumor Models'.

"We are looking forward to presenting results from our research at this outstanding conference and discussing those with experts in the field", said PD Dr. Dr. med. Oliver Grauer. "Even today, the prognosis for glioblastoma is extremely poor, since recurrence is very likely (>90%) and treatment options for patients at the time of recurrence are still limited. Most glioma recurrences are observed in the direct vicinity of the original resection cavity after the tumor has been removed. To address this, tumor cavities were, after resection, covered with superparamagnetic iron-oxide nanoparticles to create high local particle concentrations for subsequent heating in an alternating magnetic field. Patients underwent six 1-hour hyperthermia sessions and received concomitant or sequential radiotherapy. In our work we were able to demonstrate that local NanoTherm^(R) treatment combined with radiotherapy can induce a persistent inflammatory reaction at the resection cavity which might lead to long-term stabilization of recurrent GBM patients. These results warrant further investigations and we are aiming to continue investigating this interesting effect during the treatment of further patients."

MagForce will be presenting its NanoTherm^(R) therapy for the treatment of glioblastoma and other brain tumors at booth #204 in the Golden Gate foyer, Level B1 of the Marriott Marquis Hotel in San Francisco, California, USA.

Presentation Details:

About SNO 2017

The Society for Neuro-Oncology is a multidisciplinary organization dedicated to promoting advances in neuro-oncology through research and education. This year's Scientific Meeting will highlight a number of the 10 Blue Ribbon Panel recommendations related to the Cancer Moonshot program. Building on the success of past SNO meetings, sunrise sessions, plenary and concurrent sessions will be featured with oral abstract presentations, enhanced oral eTalk electronic poster presentations, and poster presentations. Special lunch tutorials and industry-sponsored symposia will provide in-depth information on evolving technologies and therapeutics. Circulated for viewing throughout the meeting will be webcasts with "Meet the Expert" recordings of esteemed scientists and clinicians on topics such as mouse models, The Cancer Genome Atlas, telomeres, genetics and epigenetics of pediatric brain tumors, and immunology checkpoint inhibitors.

In keeping with the main meeting theme, the Education Day will focus on two of the Cancer Moonshot Blue Ribbon Panel recommendations: "Developing Ways to Overcome Resistance" and "Minimizing Cancer Treatments Debilitating Side Effects." Concurrent tracks in both basic science and applied neuro-oncology will offer a comprehensive look at these two recommendations.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm^(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm^(R), NanoPlan^(R), and NanoActivator^(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com
Get to know our Technology: video (You Tube)
Stay informed and subscribe to our mailing list

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.